RocketTickers

Sangamo Announces Positive Preliminary Data

Long
NASDAQ:SGMO   Sangamo Therapeutics, Inc.
2018-08-08 16:01:00
Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.